RxDoctor Payments Data

Shawnjeet Saini, MD

Pain Medicine · Phoenix, AZNPI 1215371125

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.6% of the total across 569 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Abbott at 44.3% of the total. Reporting peaked in 2020 at $3,019 and has fallen 57.7% since, to $1,278 in 2025.

$14,044in general payments, 2019–2025

Across 569 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Boston Scientific$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$769
  • Saluda Medical Americas, Inc.$465
  • Spinal Simplicity, LLC$375
  • AbbVie$366
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1,1938%
  • Food & beverage$12,71891%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,044 in reported general payments places this provider in the 80th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$581,737
Medicare patients
590
Services billed
15,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl14$9,923
MovantikNaloxegol Oxalate11$5,210
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen99$4,032
Oxycodone Hcl214$3,514
Buprenorphine15$3,416
Fentanyl41$3,033
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$2,034
Morphine Sulfate ErMorphine Sulfate46$1,584
Gabapentin122$1,572
Pregabalin68$1,343
Lidocaine12$880
Tizanidine Hcl66$848
Celecoxib22$796
Tramadol Hcl60$718
Cyclobenzaprine Hcl64$687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl$124$4,30148 claims
Upsher-smith Laboratories LLCTopiramate$22$7817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →